Key Takeaways
- President Trump issued an executive directive instructing health authorities to accelerate psychedelic drug approval processes, sparking a sector-wide rally.
- ENVB climbed over 160% during trading, positioning itself among the top performers in psychedelic biotechnology.
- The administration pledged $50 million toward ibogaine research, a Schedule I substance under investigation for PTSD applications.
- Compass Pathways (CMPS) advanced 26.1%, AtaiBeckley (ATAI) increased 28.1%, and GH Research (GHRS) rose nearly 20%.
- RBC analyst Brian Abrahams characterized the directive as “a substantial step towards diminishing regulatory risk” for psychedelic companies.
Psychedelic biotechnology stocks experienced substantial gains Monday following President Trump’s weekend signing of an executive directive that instructs federal health authorities to expedite review procedures for psychedelic-based therapies. Enveric Biosciences (ENVB) emerged as the session’s standout performer, closing up more than 160% — a remarkable climb for a company with a market capitalization of merely $3.43 million.
Enveric Biosciences, Inc., ENVB
The executive order took a comprehensive approach rather than targeting specific companies. The directive called on the FDA and associated agencies to streamline approval pathways for psychedelic medications. This broad policy shift generated enthusiastic investor response across the entire industry.
AtaiBeckley (ATAI) surged 28.1% during premarket hours. Compass Pathways (CMPS) rose 26.1%. Definium Therapeutics (DFTX) recorded gains of 14.6%. GH Research (GHRS) advanced 19.7%. The momentum swept through the sector rapidly and comprehensively.
$50M Federal Investment in Ibogaine Research
Alongside the executive directive, Trump announced a $50 million commitment specifically for ibogaine research. Ibogaine represents a psychoactive substance extracted from an African plant species and currently maintains Schedule I classification in the United States — denoting it lacks federally approved medical applications.
This funding commitment indicates a meaningful evolution in the administration’s approach to mental health challenges, particularly post-traumatic stress disorder. Early-stage research has demonstrated ibogaine’s potential therapeutic value for PTSD, especially within veteran populations.
Compass CEO Kabir Nath responded positively to the executive directive, stating it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” RBC analyst Brian Abrahams shared this perspective, characterizing the order as “a substantial step towards diminishing regulatory risk” for the psychedelic therapeutics industry.
ENVB’s dramatic price movement arrived with meaningful background. The company had recently completed a $5 million private placement just days before — a capital raise that exceeded the company’s total market capitalization at that time. The offering consisted of 2,222,223 shares priced at $2.25 each, accompanied by two warrant series with a $2.00 per share strike price.
ENVB’s Development Pipeline and Intellectual Property
The company’s primary drug candidate, EB-003, engages 5-HT2A and 5-HT1B receptors and targets psychiatric and neurological disorders. Recently published mechanistic data demonstrated that EB-003 activates dual signaling pathways associated with antidepressant and anxiolytic properties.
ENVB recently secured a U.S. patent protecting its EVM301 molecular compounds, which encompass EB-003, alongside Canadian trademark registrations for five proprietary marks including “Enveric” and “Next Generation Mental Health.”
Should both warrant series from the private placement reach full exercise, the company stands to generate an additional $8.9 million in gross capital.
The stock’s Monday performance — exceeding 160% — captured both the sector-wide momentum from the executive directive and the strategic timing of recent fundraising that extended the company’s operational runway entering this catalytic moment.
